Corpus ID: 24182279

[Cancer of the prostate: biologic bases for the use of an antiandrogen in its treatment].

@article{Raynaud1986CancerOT,
  title={[Cancer of the prostate: biologic bases for the use of an antiandrogen in its treatment].},
  author={Jean Pierre Raynaud and Daniel Coussediere and Martine Moguilewsky and J. Pottier and Fernand Labrie},
  journal={Bulletin du cancer},
  year={1986},
  volume={73 1},
  pages={
          36-46
        }
}
Although orchiectomy, estrogens and LHRH agonists suppress testicular androgens, they are without effect on adrenal androgens which are converted into dihydrotestosterone in the prostate. It is therefore necessary to develop substances able to block the action of all androgens, whatever their source, on target organs. The non-steroid, Anandron (RU 23908), when administered orally, gives rise to a high and sustained plasma level of intact compound that inhibits testosterone binding to its… Expand
1 Citations
Controversies surrounding androgen deprivation for prostate cancer.
TLDR
Five potential pathways to the development of androgen-independent prostate cancer are described and Controversial topics of hormonal management, including immediate vs delayed hormonal therapy, monotherapy vs maximal androgen blockade (MAB), and intermittent hormonal therapy are discussed. Expand